^
Association details:
| Biomarker: | RSF1 amplification |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial
Excerpt:
...patients with high RSF1 copy number did not show benefit from adjuvant tamoxifen (HR = 1.11, interaction p = 0.09)….RSF1 amplification may predict for outcome in high-risk premenopausal breast cancer patients treated with adjuvant tamoxifen.
DOI:
10.1371/journal.pone.0081740
